Phase 3 N=584 Extended Steroid in Use in Community Acquired Pneumonia (CAP)(e)
Community Acquired Respiratory Disease Syndrome
Primary: 60-day Mortality — 50; 47; 227; 239 Participants — p=0.635
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=536 Improving CarE for Community Acquired Pneumonia 1 (ICE-CAP2)
Pneumonia Childhood
Primary: Inappropriate Disposition — 7; 6 Participants
Phase 3 N=102 The Study Of Azithromycin Switch Therapy For Treatment Of Community Acquired Pneumonia (CAP)
Community Acquired Pneumonia (CAP)
Primary: Response Rate (Clinical Response, Data Review Committee Assessment) — 86.3; 84.5; 82.9 percentage of participants
N/A N=530 Clinical Characteristics and Microbiology of Healthcare Associated Pneumonia
Healthcare Associated Pneumonia
Primary: Pathogens of Healthcare Associated Pneumonia, Measured by the Number of Participants — 15; 51; 195; 269 Participants
Phase 4 N=385 Trial to Evaluate Beta-Lactam Antimicrobial Therapy of Community Acquired Pneumonia in Children
Pneumonia
Primary: Desirability of Outcome Ranking (DOOR) — 97; 107; 47; 42 Participants — p=<0.001
Phase 2 N=158 Safety and Efficacy Study of Oxazolidinone to Treat Pneumonia
Community-Acquired Pneumonia (CAP)
Primary: Clinical Cure in the Clinically Evaluable (CE) Population at Test of Cure (TOC) — 34; 37; 32 Participants
Phase 3 N=582 Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia (CAP)
Pneumonia
Primary: Clinical Cures in the Intent to Treat Population — 217; 206; 14; 13 Participants — p=0.5667
N/A N=120 Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Community Acquired Pneumonia
Pneumonia
Primary: Use of Antibiotics in Each Group — 28; 52 participants
Early Phase 1 N=5 Procalcitonin to Reduce Antibiotic Use in Pediatric Pneumonia
Pneumonia · Pediatric Respiratory Diseases · Antibiotic Use
Primary: Total Pilot Trial Enrollment — 0; 1 Participants
Phase 2 N=33 A Phase 1b/2a Study of the Safety and Pharmacokinetics of Rhu-plasma Gelsolin in Hospitalized Subjects With CAP
Community-acquired Pneumonia
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 4; 2; 4; 3 Participants
Phase 3 N=521 Study Comparing the Safety and Efficacy of Cethromycin to Clarithromycin for the Treatment of Community-Acquired Pneumonia
Pneumonia
Primary: Clinical Cures in the Intent to Treat Population — 213; 224; 21; 9 Participants — p=0.0769
N/A N=18 PK Analysis of Moxifloxacin in the Treatment of CAP
Pneumonia
Primary: Total Peak Plasma Concentration (Cmax) — 3.99 mg/L
N/A N=1,027 Improving CarE for Community Acquired Pneumonia 1
Pneumonia Childhood
Primary: Exclusive Guideline-Concordant Antibiotic Therapy, First 24 Hours — 255; 284; 174; 120 Participants
N/A N=66 Bacterial Pneumonia Score (BPS) Guided Antibiotic Use in Children With Pneumonia and Pneumococcal Vaccine
Community Acquired Pneumonia
Primary: Use of Antibiotics in Each Group — 9; 21 participants — p=0.01
N/A N=1,821 PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older
Community Acquired Pneumonia (CAP)
Primary: Number of Participants Categorized as Cases and Controls to Determine Vaccine Effectiveness (VE) of PCV13 Against Hospitalized VT CAP: Overall — 105; 1407 Participants…
N/A N=20 Healthy Patients & Effect of Antibiotics
Microbiota · Anti-bacterial Agents
Primary: Degree of Microbial Disruption: Number of Patients With Recovery of Bacterial Species Richness at 185 Days Post-antibiotics — 3; 3; 2; 3 Participants
Phase 4 N=49 Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus
Infections
Primary: Clinical Response at Study Day 4 in the Modified Intent-to-Treat (MITT) Population — 14; 8; 16; 8 participants
Phase 3 N=342 Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia
Pneumonia, Bacterial
Primary: Number of Patients With Clinical Success as Judged by the Investigator — 158; 145; 6; 8 Participants — p==0.499
N/A N=127 Infectious Pathogens in Acute Respiratory Illness in Adults and Elderly
Respiratory Disorders
Primary: Mean Estimated Number of Acute Exacerbation of COPD (AECOPD) — 3.04 AECOPD/subject/year
N/A N=317 Retrospective Chart Review Study to Assess Characteristics, Treatment Outcomes and Resource Use of Adults Hospitalized for CAP and CSSTi Treated With Zinforo in Multiple Countries
Community Acquired Pneumonia · Complicated Skin and Soft Tissue Infection
Primary: Number of Participants With Clinical Response — 151; 118 Participants
Phase 3 N=138 Ceftobiprole in the Treatment of Pediatric Patients With Pneumonia
Community-acquired Pneumonia (CAP) · Hospital-acquired Pneumonia (HAP)
Primary: Adverse Events — 10; 5; 1; 0 Participants
N/A N=2,004 The CAPTURE Study: Validating a Unique COPD Case Finding Tool in Primary Care (Aim 3)
Chronic Obstructive Pulmonary Disease (COPD)
Primary: Proportion of CAPTURE+ Participants Who Meet a Composite Endpoint for Diagnosis and Management of COPD — 45.9; 41.9 percent — p=0.47
Phase 3 N=606 Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia
Bacterial Pneumonia
Primary: Clinical Cure Rate at Test-of-Cure (TOC) in the Modified Intent-to-Treat Efficacy (MITTE) Populations — 244; 233; 34; 58 participants
Phase 2 N=207 Study to Evaluate the Efficacy and Safety of Intravenous Infusion With Nemonoxacin Malate Sodium Chloride
Pneumonia
Primary: Difference in the Clinical Cure Rate of Two Doses of Intravenously Infused Nemonoxacin Malate Sodium Chloride Injection at Visit 4 in the mITT Population — 60; 58; 59; 7…
Phase 3 N=670 Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
Community-acquired Pneumonia · Bacterial Pneumonia
Primary: Percentage of Participants With Early Clinical Response at the Early Clinical Response (ECR) Visit — 89.6; 87.7; 8.6; 9.3 Percentage of participants
Phase 2 N=35 A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization
Pneumonia, Bacterial
Primary: Percentage of Participants With Clinical Response at Test of Cure (TOC) Visit — 90.0; 87.5; 62.5; 10.0 percentage of participants
Phase 3 N=764 A Study to Evaluate the Efficacy and Safety of Intravenous Ceftaroline Versus Intravenous Ceftriaxone in the Treatment of Adult Hospitalised Patients With Community-Acquired Bacterial Pneumonia in Asia
Community-Acquired Bacterial Pneumonia · Lung Infection of Individual Not Recently Hospitalized
Primary: Clinical Cure Rate for Ceftaroline Compared to That for Ceftriaxone at Test of Cure (TOC) in CE Population — 217; 178; 41; 62 Participants
Phase 3 N=859 Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia
Community Acquired Bacterial Pneumonia
Primary: Early Clinical Response — 383; 381 Participants
Phase 1 N=18 Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia
Community-acquired Pneumonia
Primary: Log Geometric Mean Area Under the Concentration Versus Time Curve (AUC) From Time 0 to 48 Hours After Dosing (AUC[0-48]) of Oral Omadacycline on Day 2 — 9.93 Hours x…
Phase 4 N=1,107 Rapid Empiric Treatment With Oseltamivir Study (RETOS)
Influenza · Pneumonia
Primary: Number of Participants With Clinical Failure (Failure to Reach Clinical Stability) — 6; 2 Participants — p=.460